|
1
|
Al-Hajj M, Becker MW, Wicha M, Weissman I
and Clarke MF: Therapeutic implications of cancer stem cells. Curr
Opin Genet Dev. 14:43–47. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smalley M and Ashworth A: Stem cells and
breast cancer: a field in transit. Nat Rev Cancer. 3:832–844. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke MF and Fuller M: Stem cells and
cancer: two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ponta H, Sherman L and Herrlich PA: CD44:
from adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hebbard L, Steffen A, Zawadzki V, Fieber
C, Howells N, Moll J, Ponta H, Hofmann M and Sleeman J: CD44
expression and regulation during mammary gland development and
function. J Cell Sci. 113:2619–2630. 2000.PubMed/NCBI
|
|
7
|
Aigner S, Sthoeger ZM, Fogel M, Weber E,
Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M and
Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for
P-selectin on human tumor cells. Blood. 89:3385–3395.
1997.PubMed/NCBI
|
|
8
|
Kristiansen G, Winzer KJ, Mayordomo E,
Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P,
Guski H and Dietel M: CD24 expression is a new prognostic marker in
breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
|
|
9
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. Arch Pathol Lab Med. 134:907–922. 2010.PubMed/NCBI
|
|
11
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24-/low cells in breast cancer may not be associated with
clinical outcome but may favor distant metastasis. Clin Cancer Res.
11:1154–1159. 2005.PubMed/NCBI
|
|
14
|
Mylona E, Giannopoulou I, Fasomytakis E,
Nomikos A, Magkou C, Bakarakos P and Nakopoulou L: The
clinicopathologic and prognostic significance of CD44+/CD24(−/low)
and CD44−/CD24+ tumor cells in invasive
breast carcinomas. Hum Pathol. 39:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H
and Suo Z: CD44(+)/CD24(−) cells are transit progenitors and do not
determine the molecular subtypes and clinical parameters in breast
carcinomas. Ultrastruct Pathol. 35:72–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iida N and Bourguignon LY: New CD44 splice
variants associated with human breast cancers. J Cell Physiol.
162:127–133. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naor D, Sionov RV and Ish-Shalom D: CD44:
Structure, function, and association with the malignant process.
Adv Cancer Res. 71:241–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Henniker AJ: CD24. J Biol Regul Homeost
Agents. 15:182–184. 2001.PubMed/NCBI
|
|
19
|
Fogel M, Friederichs J, Zeller Y, Husar M,
Smirnov A, Roitman L, Altevogt P and Sthoeger ZM: CD24 is a marker
for human breast carcinoma. Cancer Lett. 143:87–94. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Horiguchi K, Toi M, Horiguchi S, Sugimoto
M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K, et al:
Predictive value of CD24 and CD44 for neoadjuvant chemotherapy
response and prognosis in primary breast cancer patients. J Med
Dent Sci. 57:165–175. 2010.PubMed/NCBI
|
|
21
|
Bànkfalvi A, Terpe HJ, Breukelmann D, Bier
B, Rempe D, Pschadka G, Krech R and Böcker W: Gains and losses of
CD44 expression during breast carcinogenesis and tumour
progression. Histopathology. 33:107–116. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herrera-Gayol A and Jothy S: Adhesion
proteins in the biology of breast cancer: contribution of CD44. Exp
Mol Pathol. 66:149–156. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lockhart M Sanchez, Hajos SE, Basilio FM,
Mongini C and Alvarez E: Splice variant expression of CD44 in
patients with breast and ovarian cancer. Oncol Rep. 8:145–151.
2001.PubMed/NCBI
|
|
24
|
Looi LM, Cheah PL, Zhao W, Ng MH and Yip
CH: CD44 expression and axillary lymph node metastasis in
infiltrating ductal carcinoma of the breast. Malays J Pathol.
28:83–86. 2006.PubMed/NCBI
|
|
25
|
Honeth G, Bendahl PO, Ringnér M, Saal LH,
Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and
Hegardt C: The CD44+/CD24- phenotype is enriched in basal-like
breast tumors. Breast Cancer Res. 10:R532008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baumann P, Cremers N, Kroese F, Orend G,
Chiquet-Ehrismann R, Uede T, Yagita H and Sleeman JP: CD24
expression causes the acquisition of multiple cellular properties
associated with tumor growth and metastasis. Cancer Res.
65:10783–10793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Athanassiadou P, Grapsa D, Gonidi M,
Athanassiadou AM, Tsipis A and Patsouris E: CD24 expression has a
prognostic impact in breast carcinoma. Pathol Res Pract.
205:524–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schindelmann S, Windisch J, Grundmann R,
Kreienberg R, Zeillinger R and Deissler H: Expression profiling of
mammary carcinoma cell lines: Correlation of in vitro invasiveness
with expression of CD24. Tumour Biol. 23:139–145. 2002. View Article : Google Scholar : PubMed/NCBI
|
